News

October 21, 2020October 21, 2020

$2M NIH Grant Supports Work Into Cell Structures Linked to ALS Protein Clumps

News

A $2 million grant from the National Institutes of Health (NIH) is funding work to better understand how molecular structures called protein-RNA condensates form and are regulated within cells. ... Read more

October 20, 2020October 20, 2020

Study Identifies Environmental Risk Factors for Developing ALS

News

Head trauma, electrical burns, and hobbies involving the toxic metal lead appear to be risk factors for developing amyotrophic lateral sclerosis (ALS), a U.S.-based study found. Holding a job ... Read more

October 19, 2020October 19, 2020

AMX0035 Significantly Extends ALS Patients’ Lives, Long-term Data Show

News

Treatment with AMX0035, Amylyx’s experimental oral therapy, significantly extends the lives of amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease, according to a long-term survival analysis of the ... Read more

October 16, 2020October 16, 2020

Activities and Events Underway for AAC Awareness Month

News

October is International Augmentative and Alternative Communication (AAC) Awareness Month, set aside annually to inform the public about how amyotrophic lateral sclerosis (ALS) patients and others use these devices to ... Read more

October 15, 2020October 15, 2020

€1 Million Contest Seeks to Improve Functionality in ALS

News

With a €1 million (about $1.1 million) prize being offered, researchers are invited to join a challenge that seeks to give people with motor neuron diseases (MND) – including ... Read more

October 14, 2020October 14, 2020

Nerve Injury Progressing in Top-down Manner Evident in Bulbar ALS

News

Most people with bulbar onset amyotrophic lateral sclerosis (ALS) showed distinct signs of motor neuron injury starting in the bulbar region of the brain that controls swallowing and speaking, ... Read more

October 13, 2020October 13, 2020

Phase 2 Study of Pegcetacoplan in Recently Diagnosed Patients Opens

News

A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is now enrolling patients, Apellis Pharmaceuticals, the therapy’s developer, announced in a ... Read more

October 12, 2020October 12, 2020

BrainStorm Details Phase 3 Trial Design of NurOwn for Rapidly Progressing ALS

News

BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis ... Read more

October 9, 2020October 9, 2020

Libra Therapeutics Launches With Pipeline of 3 ALS Treatment Candidates

News

Libra Therapeutics has officially announced its launch with a platform dedicated to developing new treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company also ... Read more

October 8, 2020October 16, 2020

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

News

Scribe Therapeutics and Biogen, a biotechnology company focused on neurological diseases, have established a research partnership to develop new gene therapies for amyotrophic lateral sclerosis (ALS) using the gene-editing ... Read more

Pin It on Pinterest